Skip to main content


Generic name: lutetium Lu 177 vipivotide tetraxetan
Dosage form: injection, for intravenous use
Drug class: Therapeutic radiopharmaceuticals

Medically reviewed by Judith Stewart, BPharm. Last updated on Apr 13, 2022.

What is Pluvicto?

Pluvicto is a targeted radiopharmaceutical treatment for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body.

Pluvicto is used in patients who have already been treated with other anti-cancer treatments.

Patients will need a scan before receiving Pluvicto, using Locametz or another approved PSMA-11 imaging agent to identify the PSMA-positive lesions.


Pluvicto may cause harm to an unborn baby.

Men with female partners should use effective contraception for intercourse during treatment with Pluvicto, and for 14 weeks after the last dose.

Pluvicto may cause temporary or permanent infertility in males.

Pluvicto contributes to your overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer.

To minimize radiation exposure to others after you receive Pluvicto

Pluvicto can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia, and neutropenia. 

Pluvicto can cause severe renal toxicity. You should remain well hydrated and urinate frequently before and after administration of Pluvicto to prevent kidney injury. You will receive kidney function tests before and during your treatment.

Who should not receive Pluvicto?

You should not receive Pluvicto if you are allergic to lutetium Lu 177 vipivotide tetraxetan.

Before you receive Pluvicto

Before you receive Pluvicto, tell your doctor if you:

How will I receive Pluvicto?

Before you receive Pluvicto, you will receive a scan to identify the tumors that express PSMA.

Pluvicto is a radiopharmaceutical and your healthcare provider will take appropriate safety measures to minimize radiation exposure including the wearing of waterproof gloves and effective radiation shielding.

Pluvicto is administered via intravenous injection every 6 weeks for up to 6 doses, or until disease progression or unacceptable toxicity.

Before administration of Pluvicto patients should drink plenty of water in order to urinate as often as possible during the first hours after administration.

Dosing information

Usual Adult Dosage for Prostate Cancer

- 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses.

- Use: treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

Pluvicto side effects

Pluvicto may cause serious side effects including:

Common side effects may include:

What other drugs will affect Pluvicto?

Pluvicto is not thought to interact with other medicines.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.